Cantor Fitzgerald reissued their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $37.00 price objective on the biopharmaceutical company’s stock. ACAD has been the subject of several other reports. Robert W. Baird started coverage on shares of […]

Cantor Fitzgerald reaffirmed their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report issued on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has a $28.00 price objective on the biopharmaceutical company’s stock. MRNS has been the subject of a number of other reports. Oppenheimer reiterated a market perform rating and […]

Cantor Fitzgerald reaffirmed their overweight rating on shares of Tenet Healthcare (NYSE:THC – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $104.00 target price on the stock. A number of other brokerages also recently issued reports on THC. TheStreet upgraded shares of Tenet Healthcare from […]

Cantor Fitzgerald restated their overweight rating on shares of Biohaven (NYSE:BHVN – Free Report) in a research report released on Wednesday morning, Benzinga reports. Several other analysts have also recently commented on BHVN. JPMorgan Chase & Co. increased their price target on shares of Biohaven from $32.00 to $56.00 and gave the company an overweight […]

HC Wainwright reaffirmed their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT – Free Report) in a research note published on Wednesday, Benzinga reports. Several other equities analysts have also issued reports on RAPT. UBS Group lowered shares of RAPT Therapeutics from a buy rating to a neutral rating and cut their price objective for […]